Commitments and Contingencies (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 3 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 23, 2022
USD ($)
|
Mar. 31, 2023
USD ($)
|
Mar. 31, 2023
ILS (₪)
|
Mar. 31, 2022
USD ($)
|
Mar. 31, 2022
ILS (₪)
|
Aug. 31, 2021
USD ($)
|
Aug. 31, 2021
ILS (₪)
|
Mar. 31, 2021
USD ($)
|
Mar. 31, 2021
ILS (₪)
|
Mar. 31, 2023
USD ($)
|
Mar. 31, 2023
ILS (₪)
|
Mar. 31, 2021
ILS (₪)
|
|
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||
| Aggregate budget | $ 3,164 | ₪ 11,283 | $ 4,094 | ₪ 13,004 | $ 1,778 | ₪ 5,737 | $ 3,286 | ₪ 10,879 | ||||
| Aggregate revised budget | $ 2,118 | ₪ 6,753 | ||||||||||
| Percentage of total fund | 30.00% | 30.00% | 30.00% | 30.00% | ||||||||
| Received amount | $ 395 | ₪ 1,365 | ||||||||||
| Received amount of programs | 577 | 1,912 | ||||||||||
| Total approved grants | 9,353 | 32,068 | ||||||||||
| Total grants received | 6,960 | ₪ 23,645 | ||||||||||
| Total grants subject to royalties | 6,370 | |||||||||||
| Total contingent obligation | $ 6,640 | |||||||||||
| Received fees | $ 1,411 | |||||||||||
| Collaboration agreement, description | The fees will be paid in instalments of $500 within 30 days of the Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months after the Effective Date or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the condensed consolidated balance sheets. During the three months ended March 31, 2023, the Company recorded $125 in the condensed consolidated statements of operations as a reduction of R&D expenses. Through March 31, 2023, the Company received total funds of $500 from BI with respect to this agreement. See note 10A regarding funds received after the balance sheet date. | |||||||||||
| Minimum [Member] | ||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||
| Percentage of total fund | 30.00% | 30.00% | ||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||||
| Maximum [Member] | ||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||
| Percentage of total fund | 50.00% | 50.00% | ||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||||
| BiomX Israel [Member] | ||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||
| Received amount | $ 1,347 | ₪ 4,284 | ||||||||||